Dianthus Therapeutics (NASDAQ:DNTH) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(1.07) by 20.56 percent. This is a 3.66 percent decrease over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $463.000 thousand which beat the analyst consensus estimate of $354.214 thousand by 30.71 percent. This is a 60.19 percent decrease over sales of $1.163 million the same period last year.